

# **Retail Equity Research Zvdus Wellness Ltd.**

12 Months Investment Period

(Closing: 13-06-2024)

Rating as per Small Cap

Hold

CMP Rs. 1,862 TARGET Rs.2,046 RETURN 10% 👚

**FMCG** 

**NSE CODE: ZYDUSWELL** BSE CODE: 531335 **BLOOMBERG CODE: ZYWL:IN** SENSEX: 76,811

# Healthy demand outlook and volume upturn...

- In Q4FY24, topline grew 10% YoY to Rs.783cr due to growth in personal care & food and nutrition segment.
- EBITDA grew 12% YoY to Rs.162cr and EBITDA margin improved marginally by 40bps YoY to 21%. Management expects margins to improve over the next two years.
- PAT stood flat YoY at Rs.150cr due to higher interest and tax expenses.
- Revenue is expected to grow at 11% CAGR over FY24-26E backed by new innovations and online & offline organised trade.
- Management focuses on generating constant double-digit revenue growth through distributor expansion, consumer-centric innovations, and increased marketing activities. The company currently trades at 1 Yr Fwd PE of 30x. We value at 31x P/E (5Yr Avg = 31)on FY26E EPS of Rs.66 and recommend Hold rating on the stock with a target price of Rs.2,046.

### Topline led by healthy volume growth.....

Topline grew 10% YoY to Rs.783cr due to sustained rise in sales volume. Food and nutrition categories grew 6% YoY, while the personal care segment grew 23% YoY in Q4FY24. The key brands such as Glucon-D, Sugar Free, Nycil, Everyuth Scrub maintained their leadership position in respective categories. Glucon D maintained its No.1 position with a 59.5% market share. Complan has started showing signs of revival in the latter half of the year from a slowdown last year. The Sugar Free brand retained its leadership in the sugar substitute category with a 95.9% market share. Everyuth registered strong growth and continues to outpace segment growth. Nycil continues to be the No.1brand with a 35% market share in prickly heat powder. The company expects demand to pick up in the hope of a good monsoon and better macro-economic factors. Going ahead Revenue is expected to grow at 11% CAGR over FY24-26E backed by new innovations, online and offline organised trade and reduced cost.

### Slow rise in EBITDA margin; Focus on strengthening distribution....

EBITDA margin improved marginally by 40bps YoY. Management expects margins to improve over the next two years on account of stable raw-material prices, cost efficiencies, and better operating leverage. PAT stood flat YoY at Rs. 150cr due to higher interest and tax expenses. The management is confident on regaining growth momentum and aimed at high single digit volume growth in FY25, led by innovation, distribution and its international foray and expect margins to revert over the next two years, aided by operating leverage and softer input prices.


### **Outlook & Valuations**

Management anticipates double-digit revenue growth and margin expansion in FY25. In the medium term, the main focus is on generating constant double-digit revenue growth through distributor expansion, consumer-centric innovations, and increased marketing activities. The Scale-up of the international business and some of the new launches reaching maturity will improve growth prospects in the long run. Key brands of the company continue to maintain their strong leadership position and gain market share consistently. Margins are expected to improve with the correction in prices of key input materials. Muted performance in FY24 can be attributed to brand-specific issues, which dragged overall performance. The company currently trades at 1 Yr Fwd PE of 30x. We value at 31x (5Yr Avg = 31) and recommend Hold rating on the stock with a target price of Rs.2,046.

## Company Background...

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite. The company has been expanding its product range and market presence through organic growth and strategic acquisitions. It has also been actively involved in research and development to introduce innovative products in the wellness segment.

Company Data	
Market Cap (Rs cr)	11,463
Enterprise Value (Rs cr)	11,471
Outstanding Shares (Rs cr)	6.4
Free Float	30.4%
Dividend Yield	0.3%
52 week high	1,813
52 week low	1,425
6m average volume (cr)	0.044
Beta	0.55
Face value (Rs)	10



FY24A	FY25E	FY26E
2,315	2,592	2,896
3	12	12
308	418	503
13	16	17
267	394	422
-14	48	7
42	62	66
-16	48	7
43	29	27
2.0	2.0	1.9
30	27	23
5.1	7.0	7.2
	2,315 3 308 13 267 -14 42 -16 43 2.0 30	2,315 2,592 3 12 308 418 13 16 267 394 -14 48 42 62 -16 48 43 29 2.0 2.0 30 27

Source: Bloomberg Best post event Consensus.



# Quarterly Financials (Consolidated)

# **Profit & Loss**


Rs (cr)	Q4FY24	Q4FY23	YoY Growth %	Q3FY24	QoQ Growth %	Comments
Sales	782.6	713.0	10	403.2	94.1	Growth due to volume upturn of products
EBITDA	162.2	144.6	12	12.7	1177	
EBITDA margins(%)	20.7	20.3	40bps	3.1	1,760bps	Growth due to higher prices, softer input costs, and operating leverage
Depreciation	5.70	6.60	-14	6.10	-7	
EBIT	156.5	138.0	13	6.6	-	
Interest	6.10	5.20	17	6.30	-3	
Other Income	4.0	0.7	471	21.6	-82	
Exceptional Items	0	7				
PBT	154.4	126.3	22	3.7	-	
Tax	4.10	-19.00	-122	3.70	21	
Share of profit from Associate	0.0	0.0				
Share of profit from joint venture	0.0	0.0	0	0.0	0	
Reported PAT	150.3	145.3	3	0.3	-	
Adjustments						
Adj PAT	150.3	145.3	3	0.3	-	PAT stood flat due to higher interest and tax expenses
No. of Shares (Cr)	6.4	6.4		6.4		
EPS (Rs)	23.62	22.83	3	0.05	-	

Source: Company





### PRICE HISTORY (Last 3 Years)



#### **Investment Criteria**

Ratings	Large caps	Midcaps	Small caps
Buy	Upside is above 10%	Upside is above 15%	Upside is above 20%
Accumulate	-	Upside is between 10% - 15%	Upside is between 10% - 20%
Hold	Upside is between 0% - 10%	Upside is between 0% - 10%	Upside is between 0% - 10%
Reduce/sell	Downside is more than 0%	Downside is more than 0%	Downside is more than 0%
Not rated/Neutral		_	

#### **Definition:**

Buy: Acquire at Current Market Price (CMP), with the target mentioned in the research note. Accumulate: Partial buying or to accumulate as CMP dips in the future.

Hold: Hold the stock with the expected target mentioned in the note. Reduce: Reduce your exposure to the stock due to limited upside.

Sell: Exit from the stock. Not Rated/Neutral: The analyst has no investment opinion on the stock.

To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

The recommendations are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. Please note that the stock always carries the risk of being upgraded to BUY or downgraded to a HOLD, REDUCE or SELL.

#### **DISCLAIMER & DISCLOSURES**

**Certification**: I, Mithun T Joseph, author of this Report, hereby certify that all the views expressed in this research report reflect our personal views about any or all of the subject issuer or securities. This report has been prepared by the Research Team of Geojit Financial Services Limited, hereinafter referred to as Geojit.

For General disclosures and disclaimer: Please Visit: https://www.geojit.com/research-disclosures#fundamental-research

#### Regulatory Disclosures:

Group companies of Geojit Financial Services Limited are Geojit Technologies Private Limited (Software Solutions provider), Geojit Credits Private Limited (NBFC), Geojit Investment Limited (financial Services Company (yet to start operations)), Geojit Techloan Private Ltd( P2P lending (yet to start operations)), Geojit IFSC Ltd (a company incorporated under IFSC Regulations (yet to start operations)), Qurum Business Group Geojit Securities LLC (a joint venture in Oman engaged in Financial Services), Barjeel Geojit Financial Services LLC (a joint venture in Saudi Arabia (Under Liquidation)) and BBK Geojit Securities Co. K.S.C.C (a subsidiary in Kuwait-engaged in Financial services). In the context of the SEBI Regulations on Research Analysts (2014), Geojit affirms that we are a SEBI registered Research Entity and in the course of our business as a stock market intermediary, we issue research reports /research analysis etc. that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities.

In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

1. Disclosures regarding Ownership:

Geojit confirms that:

It/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein.

It/its associates have no actual beneficial ownership of 1% or more in relation to the subject company (ies) covered herein.

Further, the Analyst confirms that:

- (i) He, his associates and his relatives have no financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company.
- (ii) He, his associates and his relatives have no actual/beneficial ownership of 1% or more in the subject company covered.
- 2. Disclosures regarding Compensation:

During the past 12 months, Geojit or its Associates:

- (a) Have not received any compensation from the subject company; (b) Have not managed or co-managed public offering of securities for the subject company (c) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company. (d) Have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company (e) Have not received any compensation or other benefits from the subject company or third party in connection with the research report (f) The subject company is / was not a client during twelve months preceding the date of distribution of the research report.
- ${\it 3. Disclosure by Geojit\ regarding\ the\ compensation\ paid\ to\ its\ Research\ Analyst:}$

Geojit hereby confirms that no part of the compensation paid to the persons employed by it as Research Analysts is based on any specific brokerage services or transactions pertaining to trading in securities of companies contained in the Research Reports.

 ${\bf 4. \ Disclosure \ regarding \ the \ Research \ Analyst's \ connection \ with \ the \ subject \ company:}$ 

It is affirmed that I, Mithun T Joseph, Research Analyst (s) of Geojit have not served as an officer, director or employee of the subject company

5. Disclosure regarding Market Making activity:

Neither Geojit/its Analysts have engaged in market making activities for the subject company.

6. "Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."

# 7. Standard Warning: "Investment in securities market are subject to market risks. Read all the related documents carefully before investing."

Please ensure that you have read the "Risk Disclosure Documents for Capital Market and Derivatives Segments" as prescribed by the Securities and Exchange Board of India before investing.

Geojit Financial Services Ltd. Registered Office: 34/659-P, Civil Line Road, Padivattom, Kochi-682024, Kerala, India. Phone: +91 484-2901000, Website: www.geojit.com. For investor queries: customercare@geojit.com. Compliance officer: Ms. Indu K. Address: Geojit Financial Services Limited, 34/659 P, Civil Lane Road, Padivattom, Kochi – 682024; Phone: +91 484-2901367; Email: compliance@geojit.com. For grievances: Grievance Officer: Mr Nitin K; Address: Geojit Financial Services Limited,34/659 P, Civil Lane Road, Padivattom, Kochi – 682024; Phone: +91 484-2901363; Email: grievances@geojit.com. Corporate Identity Number: L67120KL1994PLC008403, SEBI Stock Broker Registration INO INZ000104737, Research Entity SEBI Reg No: INH200000345, Investment Adviser SEBI Reg No: INA200002817, Portfolio Manager: INP000003203, Depository Participant: IN-DP-325-2017, ARN Regn.Nos:0098, IRDA Corporate Agent (Composite) No.: CA0226.

